| |
|
|
|
|
|
|
|
|
1. |
Record Nr. |
UNINA9910300278803321 |
|
|
Titolo |
Antibody Therapy : Substitution – Immunomodulation – Monoclonal Immunotherapy / / edited by Paul Imbach |
|
|
|
|
|
|
|
Pubbl/distr/stampa |
|
|
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2018 |
|
|
|
|
|
|
|
|
|
ISBN |
|
|
|
|
|
|
Edizione |
[1st ed. 2018.] |
|
|
|
|
|
Descrizione fisica |
|
1 online resource (XIV, 363 p. 47 illus., 32 illus. in color.) |
|
|
|
|
|
|
Disciplina |
|
|
|
|
|
|
Soggetti |
|
Hematology |
Immunology |
Oncology |
Oncology |
|
|
|
|
|
|
|
|
Lingua di pubblicazione |
|
|
|
|
|
|
Formato |
Materiale a stampa |
|
|
|
|
|
Livello bibliografico |
Monografia |
|
|
|
|
|
Nota di contenuto |
|
The Clinical Translation of Intravenous Immunoglobulin from Substitution to Immunomodulation -- From ImmuneSubstitution to Immunomodulation -- Manual of Primary and Secondary Immunodeficiencies -- Manual of Intravenous and Subcutanous IgG Indications in Autoimmune diseases -- Anti-D IgG Concentrate; a Type of IVIg -- Mechanisms ofAction/Immunomodulation by IgG Concentrate -- Immunomodulatory Drugs and Monoclonal Antibodies -- Use of Intravenous Immunoglobulin in Neurology -- Use of Intravenous Immunoglobulin in Dermatology -- Historical Aspects ofPoliclonal IgG Preparations -- Basics of Immunoglobulins as Effector Molecules and Drugs -- Essentials of the Production of Safe and Efficacious State-of-the-Art Polyclonal IgG Concentrates -- Current IgG Products and FuturePerspectives -- Immune Thrombocytopenia: Terminology, Immunomodulation and Platelet Stimulation, ClinicalGuidelines and Management -- Health-Related Quality of life in patients with Immune Thrombocytopenia -- ITP in Childhood: Predictors of Disease Duration -- Immune Functions of Platelets -- Thrombopoietin Receptor Agonists: Characteristics, Adverse Effects and Indications -- Registries in Immune Thrombocytopenia: The History of the Intercontinental Cooperative ITP Study Group -- Monoclonal Antibodies as |
|
|
|
|
|
|
|
|
|
|
|
Immunomodulators and Anti-CancerAgents : Development, Methods, Mechanisms of Actions, Adverse Effects, List of Registered and phase II/IIIMonoclonal Antibodies Targeted to -- Monoclonal Anti-CD20 (B-Cell) Antibody and Autoimmune Diseases. |
|
|
|
|
|
|
Sommario/riassunto |
|
This practical manual, written by well-known experts, reviews current indications for the use of IgG concentrates and some other modern immunomodulators and provides fundamental information on present-day immunomodulation in patients (and mice). The book opens by tracing the transition from IgG substitution to IgG immunomodulation and providing expert updates on immunomodulatory indications in autoimmune and inflammatory disorders, including hematologic, neurologic, dermatologic, and other diseases. Basic aspects of IgG concentrates, including methods of production, safety, currently available products, and mechanisms of action, are then discussed. An entire chapter is devoted to the different aspects of immunomodulatory IgG treatment in the bleeding disorder immune thrombocytopenia (ITP). Finally, the transition from polyclonal to monoclonal antibody (mAb) treatment is addressed in detail, covering mAb development, methods, mechanisms of action, adverse effects, and more. Particular attention is paid to the example of anti-CD20 (B-cell) antibody. |
|
|
|
|
|
|
|
| |